Jay Pee Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-12-2024
- Paid Up Capital ₹ 1.00 M
as on 09-12-2024
- Company Age 13 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.50 M
as on 09-12-2024
- Revenue 10.91%
(FY 2022)
- Profit -51.99%
(FY 2022)
- Ebitda -38.91%
(FY 2022)
- Net Worth 8.98%
(FY 2022)
- Total Assets 4.18%
(FY 2022)
About Jay Pee Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.50 M.
Navneet Bhardwaj and Sushma Bhardwaj serve as directors at the Company.
- CIN/LLPIN
U24232DL2011PTC219127
- Company No.
219127
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 May 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Jay Pee Biotech Private Limited offer?
Jay Pee Biotech Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Protein Powder, Pain Relief Drugs & Pharmaceuticals, Antipyretic Medication, Vitamin Tablets & Capsules, Mineral Supplement, Dietary Supplements, Juices, Soups & Soft Drinks, Instant Drink Mix, Cardiovascular Drugs & Medication.
Who are the key members and board of directors at Jay Pee Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Navneet Bhardwaj  | Director | 13-May-2011 | Current |
| Sushma Bhardwaj | Director | 13-May-2011 | Current |
Financial Performance of Jay Pee Biotech.
Jay Pee Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 10.91% increase. The company also saw a substantial fall in profitability, with a 51.99% decrease in profit. The company's net worth moved up by a moderate rise of 8.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jay Pee Biotech?
In 2019, Jay Pee Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Feb 2021 | ₹1.50 M | Open |
How Many Employees Work at Jay Pee Biotech?
Unlock and access historical data on people associated with Jay Pee Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jay Pee Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jay Pee Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
